Canon's latest entry into the PET/CT market is a digital, air-cooled system that provides customizable solutions for a range of clients.
As the country--and the world--continues to grapple with the ongoing COVID pandemic, the imaging industry is looking to re-find its footing in an evolving landscape where customized solutions are key to success.
Enter Canon Medical's Cartesion Prime digital PET/CT, introduced in 2019, which provides a high-performance, adaptable system for today's evolving imaging technology. Optimizing both workflow and image quality via advanced silicon photomultiplier design with one-to-one coupling, fast time-of-flight and deep learning reconstruction technology, “this advanced technology has led to image quality improvements, while optimizing dose efficiency to reduce patient risk and speeding up acquisition time for improved throughput," said Tim Nicholson, managing director, Molecular Imaging Business Unit, Canon Medical Systems USA.
In an interview with Diagnostic Imaging, Nicholson expanded on the needs of the industry and how Canon is answering the call.
Possible Real-Time Adaptive Approach to Breast MRI Suggests ‘New Era’ of AI-Directed MRI
June 3rd 2025Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.